A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4 ± 3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P ¼ 0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.
INTRODUCTION
SCT is the most effective treatment for high-risk and refractory leukemia, but relapse is still a major event of allo-SCT. It is generally accepted that a second SCT is the only potentially curative approach for patients who relapse after allo-SCT, but only some patients are eligible for a second SCT because of the high mortality and morbidity associated with repeated allo-SCT. In addition, high relapse rates occur because of the resistance of leukemic cells that have not been eliminated by the first SCT. Some previous studies have examined the role of second SCT, 1 --10 but because of the small number of patients in these studies, the efficacy and safety of second allo-SCT for pediatric ALL patients that have relapsed after SCT remains unclear.
In this study, to investigate the prognostic factors of second SCT and identify subgroups for whom second SCT is effective, we performed a retrospective analysis of 171 patients who received a second SCT for relapsed ALL after allo-SCT.
PATIENTS AND METHODS

Patients and transplantations
This study was approved by the institutional ethics committee of Saitama Children's Medical Center. A total of 171 patients were analyzed based on data reported to the Japan Society for Stem Cell Transplantation registry ( Table 1 ). The patients were selected according to the following criteria: (1) children with a diagnosis of ALL who were aged 18 years or younger at the second SCT; (2) second allo-SCT was performed for ALL that relapsed after allo-SCT; and (3) both the first and second SCT were performed between 1983 and 2009.
Myeloablative conditioning was defined as TBI of 48 Gy or the administration of 48 mg/kg BU. All other regimens were analyzed as reduced intensity conditioning SCT (RIST), including low-dose TBI (8 Gy or less) and low-dose BU (8 mg/kg or less).
Statistical analysis
OS probabilities were calculated using Kaplan --Meier estimates. Non-relapse mortality (NRM) and the incidence of relapse were expressed as cumulative incidence curves to adjust the analysis for competing risks. Univariate analyses were performed using the log-rank test, and multivariate analysis was performed using the Cox proportional hazard regression model. The following variables were examined in the univariate analysis: patient age, timing of relapse after first SCT, disease status at second SCT, conditioning regimens used for first and second SCT, severity of acute GVHD, type of donor and stem cell source. The factors that were found to be significant at Po0.2 were entered into the multivariate analysis. All statistical analyses were performed with the statistical software 'R' (The R Foundation for Statistical Computing, Vienna, Austria, version 2.9.1). A two-sided P-level of o0.05 was considered statistically significant for all analyses.
RESULTS
The patients' characteristics are listed in Table 1 . The median follow-up duration of the survivors was 776 days (range, 62 --5021). In all, 45 out of 171 patients were alive at the time of our analysis, and the estimated OS probability ( ± s.e.) at 2 years was 29.4±3.7%. The cumulative incidence of relapse at 2 years was 44.1±4.0%, and NRM was 18.8±3.5% (Figure 1 ). In 34 out of 45 survivors (75.6%), the duration of remission was longer than the time to relapse after the first SCT. We identified 83 patients who relapsed after the second SCT, and remission period after the second SCT was shorter compared with that after the first SCT (median remission period was 164 days for first SCT, and 117 days for second SCT, P ¼ 0.04).
The associations between outcome and various clinical characteristics are shown in Table 2 . Young patient age at the second SCT (9 years or younger) was a prognostic factor for a good outcome. Although the difference was small, younger age was also found to be associated with better outcomes by multivariate analysis (Table 3) . Early relapse (at 180 days or earlier after the first SCT) was associated with a worse outcome (OS at 2 years; 17.7 ± 4.4%) than late relapse (180 days or more after the first SCT; 42.3 ± 5.8%) (Figure 2a ). The inferior outcomes of the patients who relapsed early after the first SCT were due to their high rate of subsequent relapse. Disease status at the second SCT was also strongly correlated with prognosis. OS at 2 years was 47.9±6.1% for patients who had achieved CR before the second SCT, whereas it was 15.3±4.3% for those that had not (P ¼ 0.0003) (Figure 2b ). The timing of relapse after the first SCT (o180 days or X180 days) and disease status at the second SCT (CR or non-CR) were correlated with each other (P ¼ 0.0001), but multivariate analysis showed that both of these factors were independently correlated with survival (Table 3) .
OS at 2 years was 41.9 ± 8.8% in the patients that had undergone myeloablative TBI as part of the second SCT, 25.2 ± 6.7 in those that underwent myeloablative BU and 28.0 ± 5.7% in those that underwent RIST (Figure 2c) . The difference between these conditioning regimens was statistically significant (P ¼ 0.003). The low OS of RIST was mainly due to the high relapse rate associated with RIST (53.2 ± 6.3% at 2 years). The conditioning regimen of the first SCT was not related to survival after the second SCT. However, the patients for whom RIST was performed during the first SCT had a tendency to achieve a better outcome. In particular, nine patients underwent RIST as part of their first SCT and myeloablative conditioning during their second SCT. These nine patients included four patients younger than 1-year old, but the detailed reason for the selection of RIST as the first SCT is unclear. Although relapse after the first SCT was occurred earlier than 180 days in six patients out of the nine patients, CR was achieved in seven out of the nine patients, and six of the seven CR patients were alive at the time of our analysis. There was no SCT of PBSC from unrelated donor. In all six patients, the remission period after the second SCT was longer than that after the first SCT. Receiving a second SCT from a related donor was associated with similar outcomes to unrelated and cord blood SCT. Receiving an SCT from a related donor was associated with low NRM, although the relapse incidence of this group tended to be higher than those of the unrelated and cord blood SCT groups. In our cohort, PBSCT was associated with worse survival than BMT (P ¼ 0.0003). No such difference was detected by multivariate analysis because there was a high proportion of non-CR patients in the PBSCT group (79.5% of patients were classified as non-CR) whereas 39.1% of BMT patients were classified as non-CR.
For the second SCT, a different donor from the first SCT was selected in 105 patients, but the second SCT using a different donor was associated with a trend toward a higher NRM and it failed to provide improvement in survival (Tables 2 and 3 ). There were 10 patients for whom SCT was performed from another HLAmatched related donor who was different from the first SCT donor, and there were 26 patients for whom SCT was performed from the same HLA-matched related donor. OS at 2 years of these two groups was similar, 37.5±16.1% for different donor group and 38.5 ± 9.5% for same donor group, respectively (P ¼ 0.47).
The severity of acute GVHD did not influence survival (Figure 2d  and Tables 2 and 3 ).
DISCUSSION
Relapse is the most frequent event of SCT for hematologic malignancies, and the prognosis of relapsed leukemia is dismal. In this study, relapse was also the most frequent event after second allo-SCT. In our cohort, most post-second SCT relapses occurred earlier than the post-first SCT relapses, indicating that the leukemia cells that were not eradicated by the first SCT were highly resistant to treatment. Consequently, we should identify prognostic factors that are useful for establishing a standard treatment strategy (move to second SCT for long-term survival or palliative treatment).
Several studies of leukemia patients who relapsed after SCT have been reported. 2, 3, 5, 11 These studies demonstrated that the duration of remission after the first SCT, conditioning regimens including TBI, and acute GVHD were prognostic factors, although most of these studies included both ALL and AML patients. A few reports included pediatric patients, and these studies showed that the outcomes and prognostic factors of second SCT were similar to those for adults. In these reports, the OS of second SCT was reported to be around 30%. 3, 9 However, the number of pediatric patients included in these previous studies was small, thus the role of second SCT remains unclear.
Our analysis revealed that pediatric ALL patients that suffer a late relapse (4180 days) after their first SCT and those who Abbreviations: NRM ¼ non-relapse mortality; RIST ¼ reduced intensity SCT. OS, relapse incidence and NRM of second SCT are shown as the mean þ s.e.
achieve CR might be able to achieve long-term survival by undergoing a second allo-SCT. Although the interval between the two SCT procedures was short in the early relapse patients, NRM was similar between the early and late relapse patients. These two factors were well correlated, and the proportion of patients that achieved CR among the patients that suffered late relapse was 64.5%, while that of the patients that suffered early relapse was 34.6%. RIST was not found to be advantageous in our analysis. It is assumed that most of the RIST patients could not undergo myeloablative conditioning because of their poor condition. Accordingly, the reduction in NRM was not sufficient to overcome their high relapse rate after RIST. Our data suggest that it is important to maintain a good performance status and organ function in order to allow the use of myeloablative conditioning regimens. In particular, SCT with myeloablative conditioning could offer a better prognosis to patients in whom RIST was performed as part of the first transplant. A previous report suggested that TBI provides better outcomes than BU, and our results showed a similar tendency, although the difference was not significant. However, it should be noted that most of the patients in whom the BU regimen was used during the second SCT suffered relapsed leukemia after SCT involving TBI. TBI is thought to be a more potent therapeutic regimen than BU, and thus leukemic cells that endure TBI are more likely to become resistant. In other words, patients who relapsed after SCT involving BU have a greater chance of being cured, especially when they have achieved CR.
Acute GVHD did not influence survival after second SCT. Severe GVHD resulted in a high NRM for patients who underwent allo-SCT twice. This result differs from those of previous studies on adult leukemia 3 and might have arisen from the fact that most of the patients in the previous studies had AML, which is known to be relatively sensitive to GVL effects. 
